PEN (Penumbra) Total Long-Term Assets: $623 Mil (As of Mar. 2026)


PEN Penumbra Inc PEN
89 GF Score
Price $318.10
GF Value $332.57
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Penumbra Total Long-Term Assets?

Penumbra PEN +0.05% 89 Total Long-Term Assets is $623 Mil as of Mar. 2026. GuruFocus rates PEN with a GF Score™ of 89/100 and a GF Value™ of $332.57 (Fairly Valued). The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Penumbra's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $623 Mil.

Penumbra Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Penumbra's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Penumbra Total Long-Term Assets Chart

Penumbra Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 562.78 615.19 640.90 582.06 609.84

Penumbra Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 593.60 609.33 602.85 609.84 623.03
PEN
89GF Score
Penumbra Inc PEN
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Penumbra Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $623 Mil mean?
Penumbra (PEN) has a Total Long-Term Assets of $623 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Penumbra and its competitors.
Is Penumbra's Total Long-Term Assets too high?
Penumbra's current Total Long-Term Assets is $623 Mil. Overall, Penumbra has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Total Long-Term Assets compare to GMED and PODD?
Penumbra's Total Long-Term Assets of $623 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Penumbra and its competitors. Penumbra's current Total Long-Term Assets is $623 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (PEN) is currently considered Fairly Valued. The stock's GF Value™ is $332.57, compared to a current price of $318.10 — trading 4.4% below its estimated fair value. The current Total Long-Term Assets is $623 Mil. Penumbra's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Penumbra (PEN), the current Total Long-Term Assets is $623 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Penumbra (PEN) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of $318.10 is trading 4.4% below its estimated GF Value™ of $332.57. GuruFocus considers Penumbra to be Fairly Valued.

Key valuation signals for PEN:

  • Total Long-Term Assets: $623 Mil
  • GF Value™: $332.57 vs. price of $318.10 (4.4% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Penumbra Business Description

Other Exchanges 0P8:Germany
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
89GF Score

Get the complete analysis for PEN

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$318.10
Price
$332.57
GF Value